Fig. 2From: Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysisOS of solid tumor patients by the severity of irAEs using the CTCAE version 4.0 (A), OS of solid tumor patients with irAEs who continued and discontinued ICIs after the first irAE occurrence (B)Back to article page